Who are CIMERLI's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Vegf Trap, Avastin, PAVBLU, JOBEVNE, VEGZELMA.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ranibizumab-eqrn.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

CIMERLI — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CIMERLI (RANIBIZUMAB-EQRN) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vascular Endothelial Growth Factor Inhibitor [EPC]. Area: Other.

marketed Vascular Endothelial Growth Factor Inhibitor [EPC] Other Live · refreshed every 30 min

Target snapshot

CIMERLI (RANIBIZUMAB-EQRN) — SANDOZ INC.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CIMERLI TARGET	RANIBIZUMAB-EQRN	SANDOZ INC	marketed	Vascular Endothelial Growth Factor Inhibitor [EPC]
Vegf Trap	AFLIBERCEPT	Regeneron	marketed	Vascular Endothelial Growth Factor Inhibitor	Vascular endothelial growth factor A	2011-01-01
Avastin	bevacizumab	Roche	marketed	Vascular Endothelial Growth Factor Inhibitor [EPC]	Vascular endothelial growth factor A	2004-01-01
PAVBLU	AFLIBERCEPT-AYYH	AMGEN INC	marketed	Vascular Endothelial Growth Factor Inhibitor [EPC]
JOBEVNE	BEVACIZUMAB-NWGD	BIOCON BIOLOGICS INC	marketed	Vascular Endothelial Growth Factor Inhibitor [EPC]
VEGZELMA	BEVACIZUMAB-ADCD	CELLTRION	marketed	Vascular Endothelial Growth Factor Inhibitor [EPC]

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vascular Endothelial Growth Factor Inhibitor [EPC] class)

AMGEN INC · 1 drug in this class
BIOCON BIOLOGICS INC · 1 drug in this class
CELLTRION · 1 drug in this class
Roche · 1 drug in this class
SANDOZ INC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CIMERLI — Competitive Intelligence Brief. https://druglandscape.com/ci/ranibizumab-eqrn. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing